LIVINGSTON, NJ--(Marketwired - October 22, 2015) - Milestone Scientific Inc.'s (NYSE: MLSS) Epidural & Intra-Articular (IA) Subsidiary today announced that it has submitted an abstract to a prestigious American pain management society in advance of their annual meeting in 2016 detailing initial results of the Company's prospective, open labeled, clinical trial assessing the CompuFlo® technology in correctly identifying the epidural space during an epidural procedure.
Milestone's Epidural & Intra-Articular (IA) Subsidiary designed the study, in conjunction with its Scientific Advisory Board, and in agreement with the U.S. Food and Drug Administration (FDA), to assess safety and effectiveness of the pressure sensing technology in identification of the epidural space.
Leonard Osser, Chief Executive Officer of Milestone Scientific, commented, "We are pleased to submit the initial results of this clinical trial and look forward to fully disclosing the data at this prestigious organization's annual meeting early next year."
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.